DALTON LUSK: Open Payments
NPI 1609500990 · BROOKLINE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$409 in 24 payments from 13 companies in 2025. Trend: 2023 $602 · 2024 $352 · 2025 $409
Food & beverage: $410
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| Novo Nordisk Inc | 3 | $57 |
| Lilly USA, LLC | 3 | $50 |
| Viatris Specialty LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Lundbeck LLC | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: BREZTRI, Ozempic, YUPELRI, TRINTELLIX, JARDIANCE, MOUNJARO, REXULTI, CAPLYTA.
Industry payments across MO — which companies pay providers there.
